J&J Win Blocking Mylan Schizophrenia Treatment Upheld on Appeal

Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit convinced a federal appeals court Mylan Laboratories Ltd.’s planned rollout of an Invega Trinza copy infringes a patent covering the schizophrenia and bipolar disorder treatment.

The US Court of Appeals for the Federal Circuit rejected arguments from Mylan critiquing a district court’s ruling that its generic treatment and associated labeling didn’t sufficiently differentiate its product from the Janssen patent. The court also disagreed with the generic-maker’s argument that Janssen’s US Patent No. 10,143,693 was obvious and therefore invalid, according to the opinion written by Judge Sharon Prost and issued by the court Friday. ...